140 related articles for article (PubMed ID: 37608916)
1. Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic
Fierro CA; Sarnecki M; Doua J; Spiessens B; Go O; Davies TA; van den Dobbelsteen G; Poolman J; Abbanat D; Haazen W
Open Forum Infect Dis; 2023 Aug; 10(8):ofad417. PubMed ID: 37608916
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI.
Fierro CA; Sarnecki M; Spiessens B; Go O; Day TA; Davies TA; van den Dobbelsteen G; Poolman J; Abbanat D; Haazen W
NPJ Vaccines; 2024 Jun; 9(1):106. PubMed ID: 38877036
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants.
Inoue M; Ogawa T; Tamura H; Hagiwara Y; Saito Y; Abbanat D; van den Dobbelsteen G; Hermans P; Thoelen S; Poolman J; Ibarra de Palacios P
Hum Vaccin Immunother; 2018; 14(9):2150-2157. PubMed ID: 29771596
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial.
Frenck RW; Ervin J; Chu L; Abbanat D; Spiessens B; Go O; Haazen W; van den Dobbelsteen G; Poolman J; Thoelen S; Ibarra de Palacios P
Lancet Infect Dis; 2019 Jun; 19(6):631-640. PubMed ID: 31079947
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L
Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461
[TBL] [Abstract][Full Text] [Related]
6. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial.
Huttner A; Hatz C; van den Dobbelsteen G; Abbanat D; Hornacek A; Frölich R; Dreyer AM; Martin P; Davies T; Fae K; van den Nieuwenhof I; Thoelen S; de Vallière S; Kuhn A; Bernasconi E; Viereck V; Kavvadias T; Kling K; Ryu G; Hülder T; Gröger S; Scheiner D; Alaimo C; Harbarth S; Poolman J; Fonck VG
Lancet Infect Dis; 2017 May; 17(5):528-537. PubMed ID: 28238601
[TBL] [Abstract][Full Text] [Related]
7. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.
Cannon K; Elder C; Young M; Scott DA; Scully IL; Baugher G; Peng Y; Jansen KU; Gruber WC; Watson W
Vaccine; 2021 Dec; 39(51):7494-7502. PubMed ID: 34839993
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
Iwata S; Kawamura N; Kuroki H; Tokoeda Y; Miyazu M; Iwai A; Oishi T; Sato T; Suyama A; François N; Shafi F; Ruiz-Guiñazú J; Borys D
Hum Vaccin Immunother; 2015; 11(4):826-37. PubMed ID: 25830489
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study.
Haranaka M; Yono M; Kishino H; Igarashi R; Oshima N; Sawata M; Platt HL
Hum Vaccin Immunother; 2023 Aug; 19(2):2228162. PubMed ID: 37389808
[TBL] [Abstract][Full Text] [Related]
10. Development and Qualification of an Opsonophagocytic Killing Assay To Assess Immunogenicity of a Bioconjugated Escherichia coli Vaccine.
Abbanat D; Davies TA; Amsler K; He W; Fae K; Janssen S; Poolman JT; van den Dobbelsteen GPJM
Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 28971965
[TBL] [Abstract][Full Text] [Related]
11. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).
Lupinacci R; Rupp R; Wittawatmongkol O; Jones J; Quinones J; Ulukol B; Dagan R; Richmond P; Stek JE; Romero L; Koseoglu S; Tamms G; McFetridge R; Li J; Cheon K; Musey L; Banniettis N; Bickham K;
Vaccine; 2023 Jan; 41(5):1142-1152. PubMed ID: 36621410
[TBL] [Abstract][Full Text] [Related]
12. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.
Dicko A; Dicko Y; Barry A; Sidibe Y; Mahamar A; Santara G; Dolo A; Diallo A; Doumbo O; Shafi F; François N; Yarzabal JP; Strezova A; Borys D; Schuerman L
Hum Vaccin Immunother; 2015; 11(9):2207-14. PubMed ID: 26020101
[TBL] [Abstract][Full Text] [Related]
13. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age.
Klein NP; Peyrani P; Yacisin K; Caldwell N; Xu X; Scully IL; Scott DA; Jansen KU; Gruber WC; Watson W
Vaccine; 2021 Sep; 39(38):5428-5435. PubMed ID: 34315611
[TBL] [Abstract][Full Text] [Related]
14. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
Platt HL; Cardona JF; Haranaka M; Schwartz HI; Narejos Perez S; Dowell A; Chang CJ; Dagan R; Tamms GM; Sterling T; Morgan L; Shi Y; Pedley A; Musey LK; Buchwald UK
Vaccine; 2022 Jan; 40(1):162-172. PubMed ID: 34507861
[TBL] [Abstract][Full Text] [Related]
15. Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age.
Hurley D; Griffin C; Young M; Scott DA; Pride MW; Scully IL; Ginis J; Severs J; Jansen KU; Gruber WC; Watson W
Clin Infect Dis; 2021 Oct; 73(7):e1489-e1497. PubMed ID: 32716500
[TBL] [Abstract][Full Text] [Related]
16. Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).
Simon JK; Staerke NB; Hemming-Harlo M; Layle S; Dagan R; Shekar T; Pedley A; Jumes P; Tamms G; Sterling T; Musey L; Buchwald UK;
Vaccine; 2022 Feb; 40(9):1342-1351. PubMed ID: 35039194
[TBL] [Abstract][Full Text] [Related]
17. A phase 3, multicenter, single-arm, open-label study to assess the safety, tolerability, and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine in Japanese participants aged 6-64 years who are considered to be at increased risk of pneumococcal disease and who are naive to pneumococcal vaccines.
Yamazaki Y; Ikeda M; Imada T; Furuno K; Mizukami T; de Solom R; Shoji Y; Oe M; Aizawa M; Giardina PC; Schmoele-Thoma B; Scott DA
Vaccine; 2021 Oct; 39(43):6414-6421. PubMed ID: 34563397
[TBL] [Abstract][Full Text] [Related]
18. Safety, reactogenicity, and immunogenicity of a 12-valent pneumococcal non-typeable
Horn M; Behre U; Traskine M; Dobbelaere K; Borys D
Hum Vaccin Immunother; 2021 May; 17(5):1463-1469. PubMed ID: 33175600
[TBL] [Abstract][Full Text] [Related]
19. Safety and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, Compared with 13-valent Pneumococcal Conjugate Vaccine in Japanese Adults Aged ≥65 Years: Subgroup Analysis of a Randomized Phase III Trial (PNEU-AGE).
Kishino H; Sawata M; Igarashi R; Shirakawa M; Pedley A; Musey L; Platt HL; Buchwald UK
Jpn J Infect Dis; 2022 Nov; 75(6):575-582. PubMed ID: 35908869
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1/2 randomized, double-blinded, controlled trial.
Clarke E; Bashorun AO; Okoye M; Umesi A; Badjie Hydara M; Adigweme I; Dhere R; Sethna V; Kampmann B; Goldblatt D; Tate A; Weiner DH; Flores J; Alderson MR; Lamola S
Vaccine; 2020 Jan; 38(2):399-410. PubMed ID: 31843266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
